Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 9,379 matching trials from the live ClinicalTrials.gov search.
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Abdominal Wall Injections on Abdominal Pain

NCT06121466
Conditions
Anterior Cutaneous Nerve Entrapment Syndrome
Interventions
Abdominal wall injections with lidocaine 2%
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
Portland, Oregon
Conditions
Crohn's Disease
Interventions
Adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 75 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
43
States / cities
La Jolla, California • San Francisco, California • Arvada, Colorado + 33 more
Conditions
Metastatic Melanoma
Interventions
vemurafenib + HD IL-2
Drug
Lead sponsor
Clinigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Tucson, Arizona • La Jolla, California • Miami Beach, Florida + 18 more
Completed Phase 2Phase 3 Interventional Results available

Selinexor in Advanced Liposarcoma

NCT02606461
Conditions
Dedifferentiated Liposarcoma
Interventions
Selinexor, Placebo
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
12 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
26
States / cities
Los Angeles, California • Santa Monica, California • Stanford, California + 18 more
Conditions
Alzheimer's Disease
Interventions
Lanabecestat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
90
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 73 more
Conditions
Tibial Fracture
Interventions
Intramedullary nail implant
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
16
States / cities
San Francisco, California • Jacksonville, Florida • Evansville, Indiana + 13 more
Conditions
Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
Interventions
Dasatinib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Depressive Disorder, Major
Interventions
onabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
35
States / cities
Little Rock, Alaska • Bellflower, California • Cerritos, California + 29 more
Conditions
Melanoma, Malignant Melanoma
Interventions
CT-011
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 9 more
Conditions
Sarcoma
Interventions
dactinomycin, busulfan, doxorubicin hydrochloride, etoposide, ifosfamide, melphalan, vincristine sulfate, autologous hematopoietic stem cell transplantation, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Leicester
Other
Eligibility
Up to 49 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 80 more
Conditions
Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Oropharynx
Interventions
Transoral surgery, intensity-modulated radiation therapy, cisplatin, carboplatin
Procedure · Radiation · Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
58
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 44 more
Conditions
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
cisplatin, paclitaxel, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-02341066
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,069 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
140
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 71 more
Conditions
Acute Undifferentiated Leukemia, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Solid Neoplasm, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Neoplasm of Uncertain Malignant Potential, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, T-Cell Large Granular Lymphocyte Leukemia
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
2,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
175
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 132 more
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone, Pentamidine isethionate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Berkeley, California • Harbor City, California • Los Angeles, California + 12 more
Conditions
Molluscum Contagiosum
Interventions
SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 24 more
Conditions
Colitis, Ulcerative
Interventions
JNJ-78934804, Guselkumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
30
States / cities
Scottsdale, Arizona • Sun City, Arizona • Anaheim, California + 27 more
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
13
States / cities
San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more
Conditions
Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
Interventions
Cebranopadol (GRT6005) Low-Dose Range, Cebranopadol (GRT6005) High-Dose Range, Placebo, Oxycodone CR
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
83
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 74 more
Conditions
Lymphoma
Interventions
filgrastim, recombinant interferon alfa, dexamethasone, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 69 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Conditions
Irritable Mood, Huntington's Disease
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Conditions
Onychomycosis
Interventions
IDP-108, Vehicle
Drug
Lead sponsor
Dow Pharmaceutical Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 29 more
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more